#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Loeys-Dietz syndrome Cutaneous T-cell lymphoma refractory Neonatal alloimmune thrombocytopenia Idiopathic inflammatory myopathy Alexander disease Systemic sclerosis pulmonary Cognitive disorder Arrhythmogenic right ventricular dysplasia Rheumatoid arthritis Wiskott-Aldrich syndrome Chronic myeloid leukaemia Demyelination Hypochromic anaemia Paroxysmal nocturnal haemoglobinuria Candida infection More trials…

    Learn about Rare Diseases

    Chondrosarcoma metastatic – Diagnostics Activated PI3 kinase delta syndrome – Trials in Disease Idiopathic inflammatory myopathy – Life with Disease Aicardi-Goutieres syndrome Propionic acidaemia Haemophilia B with anti factor IX Primary biliary cholangitis Mucopolysaccharidosis III CADASIL Gaucher’s disease type III – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Folinic Acid Clioquinol Acou085 TAGRAXOFUSP Trientine Dihydrochloride Fenebrutinib Gs-5718-03 Fremanezumab Oxazepam Vibegron Sulodexide Fluoxetine Hydrochloride Mva-209-Fsp-B1 R2R01 Rbl027.2 TX000045 Cl-Ad-Msc-002 Ertapenem Gadobenate Dimeglumine Zipalertinib More therapies…

    Learn about Your Condition

    Cholangiosarcoma Epilepsy Cardiovascular disorder Autism spectrum disorder Follicular lymphoma stage III HER2 positive breast cancer Tubulointerstitial nephritis Schizoaffective disorder Melanoma recurrent Senile dementia Implantation complication Glioma Carcinoid syndrome Hepatocellular carcinoma Mitochondrial DNA depletion More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Transitional cell carcinoma

  • Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Ibrutinib
    Czechia France Hungary Italy Poland Spain +1

  • Study on the Safety and Effectiveness of MK-2870, Enfortumab Vedotin, and Pembrolizumab for Patients with Advanced Bladder Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Antihistamines For Systemic Use
    • H2-Receptor Antagonist
    • Sacituzumab Tirumotecan
    Denmark France Italy The Netherlands Spain

  • Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • ZELENECTIDE PEVEDOTIN
    • Avelumab
    • Carboplatin
    Austria Belgium Bulgaria Czechia Denmark France +12

  • Study of Atezolizumab Treatment Before Surgery in Patients with Bladder Cancer or Upper Urinary Tract Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Atezolizumab
    France Spain

  • Study of Durvalumab and Tremelimumab for Patients with Advanced Unresectable Urothelial Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Transitional cell cancer of the renal pelvis and ureter
    • Transitional cell carcinoma
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Tremelimumab
    • Durvalumab
    • Infliximab
    Greece Spain

  • Study on the Effectiveness and Safety of Erdafitinib, Midazolam, and Metformin in Patients with Advanced Urothelial Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Erdafitinib
    • Metformin Hydrochloride
    • Midazolam
    France Spain
Previous Page
1 … 3 4 5 6 7 8
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!